Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - levetiracetam, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - levetiracetam viatris tablets are indicated for: ? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. ? add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme) and, ? add-on therapy in the treatment of primary generalised tonic-clonic seizures (pgtc) in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - levetiracetam, quantity: 250 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - levetiracetam viatris tablets are indicated for: ? use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. ? add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme) and, ? add-on therapy in the treatment of primary generalised tonic-clonic seizures (pgtc) in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

Israel - English - Ministry of Health

propharm ltd - levetiracetam - concentrate for solution for infusion - levetiracetam 100 mg / 1 ml - levetiracetam - levetiracetam altan 100 mg/ml is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.levetiracetam altan 100 mg/ml is indicated as adjunctive therapy•in the treatment of partial onset seizures with or without secondary generalization in adults, adolescents patients and children from 4 years of age with epilepsy.•in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy•in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalized epilepsy.levetiracetam altan 100 mg/ml is an alternative for patients when oral administration is temporarily not feasible.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levetiracetam, quantity: 10 % w/v - oral liquid, solution - excipient ingredients: acesulfame potassium; propyl hydroxybenzoate; purified water; maltitol solution; glycerol; sodium citrate dihydrate; methyl hydroxybenzoate; ammonium glycyrrhizinate; citric acid monohydrate; flavour - levetiracetam-aft oral solution is indicated for:,use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and,add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).,levetiracetam-aft concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - levetiracetam, quantity: 1000 mg - tablet, film coated - excipient ingredients: maize starch; colloidal anhydrous silica; croscarmellose sodium; povidone; microcrystalline cellulose; purified talc; magnesium stearate; titanium dioxide; macrogol 6000; polyvinyl alcohol; macrogol 3350 - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - levetiracetam, quantity: 500 mg - tablet, film coated - excipient ingredients: maize starch; colloidal anhydrous silica; croscarmellose sodium; povidone; microcrystalline cellulose; purified talc; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 6000; polyvinyl alcohol; macrogol 3350 - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - levetiracetam, quantity: 250 mg - tablet, film coated - excipient ingredients: maize starch; colloidal anhydrous silica; croscarmellose sodium; povidone; microcrystalline cellulose; purified talc; magnesium stearate; titanium dioxide; macrogol 6000; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add-on therapy in the treatment of primary generalized tonic clonic (pgtc) seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - levetiracetam - epilepsy - antiepileptics, - levetiracetam is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.levetiracetam is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

European Union - English - EMA (European Medicines Agency)

actavis group ptc ehf - levetiracetam - epilepsy - antiepileptics, - levetiracetam actavis is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.levetiracetam actavis is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

European Union - English - EMA (European Medicines Agency)

actavis group ptc ehf - levetiracetam - epilepsy - antiepileptics, - levetiracetam actavis group is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.levetiracetam actavis group is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from 1 month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.